AMPAC Fine Chemicals expands production with plant in Texas
The addition of these facilities increases the firm’s total reactor capacity by approximately 30%
AMPAC Fine Chemicals has expanded its California-based pharmaceutical chemicals business into LaPorte, Texas.
The LaPorte plant is a multi-purpose manufacturing facility specialising in the production of intermediates and active pharmaceutical ingredients (APIs). The plant performs energetic chemistry at large scale and has been successfully inspected by the US Food and Drug Administration, most recently in 2008.
These cGMP manufacturing facilities were completed in 2001 and significant new equipment has been added in the last four years.
The addition of these facilities will increase AMPAC Fine Chemicals’ total reactor capacity by approximately 30%. The plant was bought by its parent company, American Pacific Corporation, on 9 April for US$475,000.
‘This additional capability in Texas, which includes commercial scale hydrogenation, as well as azide, cyanide, and phosgene capabilities, fits well with our areas of established expertise in energetic chemistry and continuous processing,’ said Aslam Malik, president of AMPAC Fine Chemicals.
‘While it will take some time to fill this expanded capacity, our pipeline remains strong and we foresee the need for this capacity as our development products mature.’
